 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...5354555657585960616263...100101» |
- ||||| Piqray (alpelisib) / Novartis
Clinical: Alpelisib/Letrozole Retains Efficacy in PIK3CA-Mutant HR+ Advanced Breast Cancer Post-CDK4/6 Inhibition/Fulvestrant @hoperugo @UCSFCancer @SABCSSanAntonio #SABCS #bcsm https://t.co/cRNgygs0Ty (Twitter) - Dec 10, 2020
- || Clinical, Journal: Oocyte cryopreservation in the setting of a vascular endothelial growth factor (VEGF)-producing paraneoplastic syndrome: a case report and review of literature. (Pubmed Central) - Dec 10, 2020
Oocyte cryopreservation was successful and without complications due to a combination of prophylactic measures against OHSS (cabergoline, letrozole and GnRH-A trigger) and close collaboration between reproductive endocrinology and oncology. This case demonstrates the use of combined measures in targeting VEGF overproduction and OHSS risk during COH.
- || letrozole / Generic mfg.
Clinical, Journal: Complete remission from peritoneal metastasis of late recurrent breast cancer by endocrine therapy: a case report. (Pubmed Central) - Dec 10, 2020
This case demonstrates the use of combined measures in targeting VEGF overproduction and OHSS risk during COH. A rare case of late-phase metachronous peritoneal metastasis of the breast cancer where complete remission was obtained by a single endocrine agent was presented.
- || Itovebi (inavolisib) / Roche
Enrollment change, Trial completion date, Trial primary completion date: GO39374: To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (clinicaltrials.gov) - Dec 10, 2020
P1, N=256, Recruiting, Sponsor: Genentech, Inc.
A rare case of late-phase metachronous peritoneal metastasis of the breast cancer where complete remission was obtained by a single endocrine agent was presented. N=104 --> 256 | Trial completion date: Dec 2020 --> Nov 2022 | Trial primary completion date: Dec 2020 --> Nov 2022
- | letrozole / Generic mfg.
Enrollment open: Letrozole in Patients With Hepatopulmonary Syndrome (clinicaltrials.gov) - Dec 10, 2020
P2, N=20, Recruiting, Sponsor: Mayo Clinic
N=104 --> 256 | Trial completion date: Dec 2020 --> Nov 2022 | Trial primary completion date: Dec 2020 --> Nov 2022 Not yet recruiting --> Recruiting
- |||| Piqray (alpelisib) / Novartis
Incoraggianti i risultati della coorte B di #BYLieve. Sopravvivenza libera da progressione di 5,6 mesi con #alpelisib a #letrozole per i casi pluritrattati e con mutazione di #PIK3CA. #SABCS20 @vitti10 (Twitter) - Dec 9, 2020
- |||||| Piqray (alpelisib) / Novartis
Clinical: Additional data on alpelisib in PIK3CA mutant breast cancer following progression on CDK4/6i - some efficacy for alpelisib + letrozole despite prior progression on AI. Discussion by @vitti10 on BYLieve abstract by @hoperugo and colleagues. #SABCS20 #bcsm (Twitter) - Dec 9, 2020
- | Ibrance (palbociclib) / Pfizer
Letrozole and Ibrance working like a champ for me! (Twitter) - Dec 9, 2020
- ||| PF-07248144 / Pfizer
Enrollment open, Metastases: C4551001: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 7, 2020
P1, N=110, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | hydrocortisone / Generic mfg., flutamide / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Dec 4, 2020
P2, N=62, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Phase classification, Enrollment change: Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Dec 4, 2020
P1/2, N=79, Completed, Sponsor: University of California, San Francisco
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Phase classification: P=N/A --> P1/2 | N=56 --> 79
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment open: Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov) - Dec 3, 2020
P2, N=32, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Phase classification: P=N/A --> P1/2 | N=56 --> 79 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Dec 3, 2020
P=N/A, N=109, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Trial completion date: Sep 2020 --> Sep 2021
- | everolimus / Generic mfg.
Trial completion, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Dec 3, 2020
P3, N=110, Completed, Sponsor: Istituto Oncologico Veneto IRCCS
Trial completion date: Sep 2020 --> Sep 2021 Active, not recruiting --> Completed
- || letrozole / Generic mfg.
Retrospective data, Review, Journal: Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. (Pubmed Central) - Dec 2, 2020
Randomized controlled trials (RCTs) comparing 10 adjuvant treatments [testosterone, dehydroepiandrosterone (DHEA), letrozole, recombinant LH, recombinant hCG, oestradiol, clomiphene citrate, progesterone, growth hormone (GH) and coenzyme Q10 (CoQ10)] were included...For patients with POR, controlled ovarian stimulation protocols using adjuvant treatment with DHEA, CoQ10 and GH showed better clinical outcomes in terms of achieving pregnancy, and a lower dosage of gonadotrophin required for ovulation induction. Furthermore, high-level RCT studies using uniform standards for POR need to be incorporated into future meta-analyses.
- | Ibrance (palbociclib) / Pfizer
Journal: An unusual durable response with palbociclib plus letrozole in hormone receptor positive metastatic breast cancer after multiple lines of therapy. (Pubmed Central) - Dec 2, 2020
Furthermore, high-level RCT studies using uniform standards for POR need to be incorporated into future meta-analyses. No abstract available
- || metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Dec 2, 2020
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
No abstract available Trial completion date: Oct 2020 --> Oct 2023 | Trial primary completion date: Oct 2020 --> Oct 2022
- Kisqali (ribociclib) / Novartis
[VIRTUAL] Free work: Updated results of the CompLEEment-1 Phase IIIb study of Ribociclib plus Letrozole for the treatment of HR + HER2- advanced breast cancer. () - Nov 28, 2020 - Abstract #CDDS2020CDDS_33;
- || letrozole / Generic mfg.
Clinical, Journal: Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome. (Pubmed Central) - Nov 27, 2020
LTZ is superior to CC in terms of pregnancy rates and live birth rates. As a result, we recommend that LTZ should be the first-line treatment agent in patients with PCOS.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Nov 27, 2020
P2, N=377, Active, not recruiting, Sponsor: MedSIR
As a result, we recommend that LTZ should be the first-line treatment agent in patients with PCOS. Trial primary completion date: Jul 2020 --> Dec 2020
- ||||| Ibrance (palbociclib) / Pfizer
Video: VIDEO: ENGOT-EN3-NSGO/PALEO: Letrozole-palbociclib combination for #EndometrialCancer w/ @MirzaCPH of @UCPH_health: https://t.co/TA282dPTL3 @VJOncology @myESMO @OncoAlert #ESMO20 #OncoAlert (Twitter) - Nov 27, 2020
- | tamoxifen / Generic mfg.
Reimbursement, Journal, Medicaid: The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. (Pubmed Central) - Nov 26, 2020
Trial primary completion date: Jul 2020 --> Dec 2020 Medicaid expansion may have had a meaningful impact on the ability of lower-income women to access effective hormonal therapies used to treat breast cancer.
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica
Biomarker, Clinical, P3 data, Journal: Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. (Pubmed Central) - Nov 26, 2020
P3
POAI has not been shown to improve treatment outcome, but can be used without detriment to help select appropriate adjuvant therapy based on tumour Ki67. Most patients with low Ki67 or low POAI-induced Ki67 do well with adjuvant standard endocrine therapy (giving consideration to clinical-pathological factors), whereas those whose POAI-induced Ki67 remains high might benefit from further adjuvant treatment or trials of new therapies.
- || Clinical, Journal, HEOR: The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. (Pubmed Central) - Nov 25, 2020
In the scenario 2, the situation was similar to the scenario 1, but with lowest costs for ribociclib per month PFS-gained both at full dose (2070 €) and at dose reduction (1391 € and 690 € at 400 mg and 200 mg, respectively). Combining pharmacological costs of drugs with the measure of efficacy represented by the PFS, ribociclib was the less expensive in both scenarios.
- || Ibrance (palbociclib) / Pfizer
Enrollment closed: Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) (clinicaltrials.gov) - Nov 25, 2020
P2, N=195, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Combining pharmacological costs of drugs with the measure of efficacy represented by the PFS, ribociclib was the less expensive in both scenarios. Recruiting --> Active, not recruiting
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, HEOR, Patient reported outcomes, Metastases: PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) - Nov 25, 2020
P4, N=960, Recruiting, Sponsor: Palleos Healthcare GmbH
Recruiting --> Active, not recruiting Trial completion date: Mar 2025 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Jun 2027
- Ibrance (palbociclib) / Pfizer, Kadcyla (ado-trastuzumab emtansine) / Roche
Enrollment closed, Trial primary completion date, Metastases: Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (clinicaltrials.gov) - Nov 25, 2020
P1/2, N=3, Active, not recruiting, Sponsor: University of Kansas Medical Center
Trial completion date: Mar 2025 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Jun 2027 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2025 --> Mar 2020
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Nov 24, 2020
P3, N=496, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2025 --> Mar 2020 Trial primary completion date: May 2021 --> May 2023
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Enrollment open: Pharmacokinetics and Hepatic Safety of EGCG (clinicaltrials.gov) - Nov 24, 2020
P1, N=36, Recruiting, Sponsor: Yale University
Trial primary completion date: May 2021 --> May 2023 Not yet recruiting --> Recruiting
- ||| Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer (clinicaltrials.gov) - Nov 23, 2020
P2, N=75, Completed, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
Enrollment open: Combined Immunotherapies in Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Nov 22, 2020
P2, N=102, Recruiting, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Herceptin (trastuzumab) / Roche
Clinical, P2 data, Journal: TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer. (Pubmed Central) - Nov 19, 2020
P2
Treatment with dual anti-HER2 therapy for 24 weeks led to a numeric increase in pCR rate in women with HER2-positive breast cancer, without using chemotherapy. If validated, this approach may help identify patients who may benefit from de-escalation of therapy.
- || letrozole / Generic mfg., aspirin / Generic mfg.
Clinical, Review, Journal: Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. (Pubmed Central) - Nov 18, 2020
In fresh synchronised oocyte donor cycles, the clinical pregnancy rate is probably improved and cycle cancellation rates are probably reduced when starting progestogen the day of or day after donor oocyte retrieval. Adequately powered studies are needed to evaluate each treatment more accurately.
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion date: Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4) (clinicaltrials.gov) - Nov 16, 2020
P3, N=2056, Active, not recruiting, Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Adequately powered studies are needed to evaluate each treatment more accurately. Trial completion date: Aug 2020 --> Aug 2022
- | Tecentriq (atezolizumab) / Roche
New P1 trial, PD(L)-1 Biomarker: AteBrO: Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity (clinicaltrials.gov) - Nov 15, 2020
P1, N=120, Not yet recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- | letrozole / Generic mfg.
Journal: Morphological and Functional Changes in Skin of Adult Male Rats Chronically Treated with Letrozole, a Nonsteroidal Inhibitor of Cytochrome P450 Aromatase. (Pubmed Central) - Nov 14, 2020
This study indicates that estrogens exert an effect via ERs that has a role in maintaining proper skin morphology in males, together with androgen. This is also the first documented expression of FSHR in the skin of male rats.
- | letrozole / Generic mfg.
Journal: Folic acid receptor-targeted solid lipid nanoparticles to enhance cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment. (Pubmed Central) - Nov 14, 2020
Taken together, these findings indicated the evidence of apoptosis as a mechanism of cell death. This study suggests the potential of FA-SLNs-LTZ for inducing apoptosis in a target-specific manner with minimal systemic side effects.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal: Unusual recurrent metastasizing benign breast papilloma: a case report. (Pubmed Central) - Nov 14, 2020
We present an unusual case of multiple recurrent peripheral papillomas with entirely benign histologic features exhibiting malignant behavior over a protracted period of many years, with an invasion of pectoralis musculature and possibly internal mammary and mediastinal nodes. Her treatment course included multiple surgeries (ultimately mastectomy), radiation therapy, and endocrine therapy.
- Tepezza (teprotumumab-trbw) / Roche, Amgen
Trial termination, Combination therapy, Metastases: A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Nov 13, 2020
P2, N=6, Terminated, Sponsor: Hoffmann-La Roche
Her treatment course included multiple surgeries (ultimately mastectomy), radiation therapy, and endocrine therapy. Completed --> Terminated; Due to the discontinuation of compound development, this study has been terminated.
- ||| Piqray (alpelisib) / Novartis
Enrollment open, Metastases: METALLICA: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (clinicaltrials.gov) - Nov 13, 2020
P2, N=68, Recruiting, Sponsor: MedSIR
Completed --> Terminated; Due to the discontinuation of compound development, this study has been terminated. Active, not recruiting --> Recruiting
- || letrozole / Generic mfg.
@DrAhmedAlShehri السلام عليكم دكتور . والدتي الله يطولنا بعمرها انتهت من الكيمو لها 7 شهور و بعدها اخذت حبوب " فيمابلكس " والان تاخذ حبوب letrozole “وتحس ب الحر و حكة بالجسم !؟ هل هي من مضاعفات هالحبوب ! ومالحل ؟؟ (Twitter) - Nov 12, 2020
- | letrozole / Generic mfg.
Journal: Initial studies with [C]vorozole positron emission tomography detect over-expression of intra-tumoral aromatase in breast cancer. (Pubmed Central) - Nov 12, 2020
Tracer injection and scanning were repeated 2 h after ingestion of 2.5 mg of letrozole...Tumors with high SUV in vivo also showed high staining intensity on IHC. PET with C-vorozole is a useful technique for measuring aromatase expression in individual breast lesions, enabling a non-invasive quantitative measurement of baseline and post-treatment aromatase availability in primary tumors and metastatic lesions.
- || Stimuvax (tecemotide) / EMD Serono, Seattle Genetics
Clinical, P2 data, Journal: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). (Pubmed Central) - Nov 12, 2020
PET with C-vorozole is a useful technique for measuring aromatase expression in individual breast lesions, enabling a non-invasive quantitative measurement of baseline and post-treatment aromatase availability in primary tumors and metastatic lesions. Neoadjuvant tecemotide is safe, but does not improve RCB or pCR rates in patients receiving standard neoadjuvant therapy.
- | Eligard (leuprolide acetate) / TOLMAR, Astellas, Sanofi
Journal: Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. (Pubmed Central) - Nov 12, 2020
Neoadjuvant tecemotide is safe, but does not improve RCB or pCR rates in patients receiving standard neoadjuvant therapy. This study showed the important roles of ERα in tumor progression and endocrine therapies of pancreatic cancer in women.
- || Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
Clinical, Journal: Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report. (Pubmed Central) - Nov 11, 2020
We hope to provide an attractive evidence for neoadjuvant endocrine therapy of neuroendocrine carcinoma of the breast. However, more cases are still being needed for research.
- || letrozole / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Evaluation of IM Letrozole ISM (clinicaltrials.gov) - Nov 9, 2020
P1, N=120, Active, not recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
However, more cases are still being needed for research. Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Jan 2021 | Trial primary completion date: Jul 2020 --> Jan 2021
- | metformin / Generic mfg.
Journal: Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway. (Pubmed Central) - Nov 7, 2020
LWDH Pills therapy obviously improved the ovarian polycystic pathogenesis and regained the development of follicles via upregulating Cyp19a1, alleviated insulin resistance through acting on PI3K/Akt signaling pathway. These findings have provided scientific evidence for LWDH Pills to treat PCOS.
- || letrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. (Pubmed Central) - Nov 6, 2020
Our results suggest the AroER tri-screen to be a very sensitive method to estimate the overall estrogen-mediated activity in human samples even during therapy with highly potent aromatase inhibitors. In the present study, serum estrogen activity was significantly higher during exemestane therapy when compared to letrozole therapy.
- || letrozole / Generic mfg.
Clinical, P2 data, Journal, Tumor-Infiltrating Lymphocyte, IO Biomarker: Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. (Pubmed Central) - Nov 6, 2020
P3
Increasing TILs during letrozole was significantly associated with a poor treatment response. An increase in TILs during endocrine therapy might imply immunogenicity, and these patients could be targetable by immunotherapy.
- | Z-endoxifen hydrochloride / Jina Pharma
Journal: Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. (Pubmed Central) - Nov 6, 2020
In endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen results in robust antitumor and antiestrogenic activity compared to tamoxifen and aromatase inhibitor monotherapy. These data support the ongoing development of Z-endoxifen.